Phase I/II study of gefitinib and capecitabine in patients with colorectal cancer

Clinical and Translational Oncology

Volumn 10, Issue 1, 2008, Pages 52-57

  Jimeno, Antonio ^a   Grávalos, Cristina ^b   Escudero, Pilar ^c   Sevilla, Isabel ^d   Vega Villegas, Eugenia M ^e   Alonso, Vicente ^f   Juez, Ignacio ^g   García Carbonero, Rocío ^h   Bovio, Humberto ⁱ   Colomer, Ramón ^g   Cortés Funes, Hernán ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^d HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^e HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^f HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^g CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^h HOSPITAL SEVERO OCHOA   (Spain)

ⁱ ASTRAZENECA   (United Kingdom)

Author keywords

Capecitabine; Colorectal cancer; EGFR; Gefitinib

Indexed keywords

CAPECITABINE; GEFITINIB; HEMOPOIETIC GROWTH FACTOR; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; FLUOROURACIL; QUINAZOLINE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HEMATOLOGIC DISEASE; HUMAN; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RECOMMENDED DRUG DOSE; SIDE EFFECT; THROMBOCYTOPENIA; COLORECTAL TUMOR; MIDDLE AGED; MORTALITY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; QUINAZOLINES;

EID: 43249098618     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-008-0153-5     Document Type: Article

References (22)

1. Kono A, Hara Y, Sugata S et al (1983) Activation of 5′-deoxy-5-fluorouridine by thymidine phosphorylase in human tumors. Chem Pharm Bull (Tokyo) 31:175-178
2. Takebayashi Y, Yamada K, Miyadera K et al (1996) The activity and expression of thymidine phosphorylase in human solid tumours. Eur J Cancer 32A:1227-1232
3. Ishikawa T, Utoh M, Sawada N et al (1998) Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem Pharmacol 55:1091-1097
4. Ishikawa T, Sekiguchi F, Fukase Y et al (1998) Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res 58:685-690
5. Hoff PM, Ansari R, Batist G et al (2001) Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study. J Clin Oncol 19:2282-2292
6. Van Cutsem E, Hoff PM, Harper P et al (2004) Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: Integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer 90:1190-1197
7. Diaz-Rubio E, Tabernero J, Gomez-Espana A et al (2007) Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: Final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. J Clin Oncol 25:4224-4230
8. Porschen R, Arkenau HT, Kubicka S et al (2007) Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: A final report of the AIO Colorectal Study Group. J Clin Oncol 25:4217-4223
9. Saltz LB, Clarke E, Diaz-Rubio E et al (2007) First efficacy and safety results from XELOX-1/NO16966, a randomised 2×2 factorial phase III trial of XELOX vs FOLFOX4+bevacizumab or placebo in first-line metastatic colorectal cancer. Proc Gastrointestinal Cancer Symposium
10. Magne N, Fischel JL, Dubreuil A et al (2003) ZD1839 (Iressa) modifies the activity of key enzymes linked to fluoropyrimidine activity: rational basis for a new combination therapy with capecitabine. Clin Cancer Res 9:4735-4742
11. Barker AJ, Gibson KH, Grundy W et al (2001) Studies leading to the identification of ZD 1839 (IRESSA): An orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg Med Chem 11:1911-1914
12. Liu G, Franssen E, Fitch MI, Warner E (1997) Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 15:110-115
13. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
14. Kaplan E, Meier P (1958) Nonparametric estimation for incomplete observations. J Am Soc Stat Assoc 53:447
15. Erlichman C, Hidalgo M, Boni JP et al (2006) Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors. J Clin Oncol 24:2252-2260
16. Cunningham D, Humblet Y, Siena S et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345
17. Rothenberg ML, Oza AM, Bigelow RH et al (2003) Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: Interim results of a phase III trial. J Clin Oncol 21:2059-2069
18. Hoff PM, Pazdur R, Lassere Y et al (2004) Phase II study of capecitabine in patients with fluorouracil-resistant metastatic colorectal carcinoma. J Clin Oncol 22:2078-2083
19. Rothenberg ML, LaFleur B, Levy DE et al (2005) Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma. J Clin Oncol 23:9265-9274
20. Saltz LB (2005) Can the addition of cetuximab to irinotecan improve outcome in colorectal cancer? Nat Clin Pract Oncol 2:20-21
21. Kuo T, Cho CD, Halsey J et al (2005) Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer. J Clin Oncol 23:5613-5619
22. Van Schaeybroeck S, Karaiskou-McCaul A, Kelly D et al (2005) Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy. Clin Cancer Res 11:7480-7489